CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB1907 : TKKK]

21829 Wu MJ, Kondo H, Kammula AV, Shi L, Xiao Y, Dhiab S, Xu Q, Slater CJ, Avila OI, Merritt J, Kato H, Kattel P, Sussman J, Gritti I, Eccleston J, Sun Y, Cho HM, Olander K, Katsuda T, Shi DD, Savani MR, Smith BC, Cleary JM, Mostoslavsky R, Vijay V, Kitagawa Y, Wakimoto H, Jenkins RW, Yates KB, Paik J, Tassinari A, Saatcioglu DH, Tron AE, Haas W, Cahill D, McBrayer SK, Manguso RT, Bardeesy N. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science 2024 385(6705):eadl6173 PubMed ID: 38991060 DOI: 10.1126/science.adl6173

20228 Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma. Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y. Cancer Med 2021 PubMed ID: 34245137 DOI: 10.1002/cam4.4121

20122 Hendaoui I, Lahmar A, Campo L, Mebarki S, Bichet S, Hess D, Degen M, Kchir N, Charrada-Ben Farhat L, Hefaiedh R, Ruiz C, Terracciano LM, Tucker RP, Hendaoui L, Chiquet-Ehrismann R. Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers. Front Immunol 2020 11:630139 PubMed ID: 33692777 DOI: 10.3389/fimmu.2020.630139

19470 Lau DK, Mouradov D, Wasenang W, Luk IY, Scott CM, Williams DS, Yeung YH, Limpaiboon T, Iatropoulos GF, Jenkins LJ, Reehorst CM, Chionh F, Nikfarjam M, Croagh D, Dhillon AS, Weickhardt AJ, Muramatsu T, Saito Y, Tebbutt NC, Sieber OM, Mariadason JM. Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets iScience 2019 21:624-637 PubMed ID: 31731200 DOI: 10.1016/j.isci.2019.10.044

3737 Sakamoto Y, Yamagishi S, Okusaka T, Ojima H. Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines. Cells 2019 8(9):1026 PubMed ID: 31484399 DOI: 10.3390/cells8091026

10759 Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H. PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay. Jpn. J. Clin. Oncol. 2018 48:396-399 PubMed ID: 29474549 DOI: 10.1093/jjco/hyy011

10290 Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Mol. Carcinog. 2017 56:2146-2157 PubMed ID: 28467612 DOI: 10.1002/mc.22671

3727 Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines. Mol Oncol 2017 11(9):1130-1142 PubMed ID: 28544747 DOI: 10.1002/1878-0261.12078

14252 Maki T, Ikeda H, Kuroda A, Kyogoku N, Yamamura Y, Tabata Y, Abiko T, Tsuchikawa T, Hida Y, Shichinohe T, Tanaka E, Kaga K, Hatanaka K, Matsuno Y, Imai N, Hirano S. Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification Int J Oncol 2017 50(1):129-140. PubMed ID: 27922671 DOI: 10.3892/ijo.2016.3786

14528 Yagai T, Matsui S, Harada K, Inagaki FF, Saijou E, Miura Y, Nakanuma Y, Miyajima A, Tanaka M. Expression and localization of sterile alpha motif domain containing 5 is associated with cell type and malignancy of biliary tree PLoS One 2017 12(4):e0175355 PubMed ID: 28388653 DOI: 10.1371/journal.pone.0175355

3735 Saha SK et al Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discov 2016 6(7):727-39 PubMed ID: 27231123 DOI: 10.1158/2159-8290.CD-15-1442

7256 Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, Okura R, Kobayashi K, Tadokoro T, Mimura S, Nomura T, Miyoshi H, Morishita A, Kamada H, Yoneyama H, Okano K, Suzuki Y, Masaki T. Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. Int. J. Oncol. 2015 47:1293-302 PubMed ID: 26252371 DOI: 10.3892/ijo.2015.3118

3736 Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T. Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma. Mol Cancer Ther. 2015 14(9):1985-93 PubMed ID: 26141945 DOI: 10.1158/1535-7163.MCT-15-0069

10985 Kumai T, Ohkuri T, Nagato T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Celis E, Harabuchi Y, Kobayashi H. Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma Sci Rep 2015 5:16280 PubMed ID: 26538233 DOI: 10.1038/srep16280

12541 Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T. ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma Hepatol Res 2014 44(14):E320-34 PubMed ID: 24552196 DOI: 10.1111/hepr.12312

13689 Takahashi H, Ojima H, Shimizu H, Furuse J, Furukawa H, Shibata T. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma Jpn J Clin Oncol 2014 44(6):570-8 PubMed ID: 24755544 DOI: 10.1093/jjco/hyu045

14930 Takahashi N, Aoyama F, Hiyoshi M, Kataoka H, Sawaguchi A. Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater Int J Oncol 2014 44(4):1139-45 PubMed ID: 24481592 DOI: 10.3892/ijo.2014.2282

18721 Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Asahina D, Ushigome M, Hiraoka N, Nagino M, Kondo T. Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma J Proteomics 2012 75(5):1577-89 PubMed ID: 22155129 DOI: 10.1016/j.jprot.2011.11.030

3722 Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers. Cancer Sci 2012 103(2):252-61 PubMed ID: 22044563 DOI: 10.1111/j.1349-7006.2011.02138.x

7767 Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T. Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br. J. Cancer 2011 105:131-8 PubMed ID: 21673683 DOI: 10.1038/bjc.2011.199

7862 Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci 2011 18:700-11 PubMed ID: 21451941 DOI: 10.1007/s00534-011-0376-7

13667 Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment Cancer Sci 2010 101(4):882-8 PubMed ID: 20088962 DOI: 10.1111/j.1349-7006.2009.01462.x

18737 Kawase H, Fujii K, Miyamoto M, Kubota KC, Hirano S, Kondo S, Inagaki F. Differential LC-MS-based proteomics of surgical human cholangiocarcinoma tissues J Proteome Res 2009 8(8):4092-103 PubMed ID: 19569727 DOI: 10.1021/pr900468k

3705 Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y. Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer. World J Gastroenterol 2009 15(31):3865-73 PubMed ID: 19701966 DOI: 10.3748/wjg.15.3865

6410 Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y. Is parainfluenza virus a threatening virus for human cancer cell lines? Hum Cell 2009 22(3):81-4 PubMed ID: 19624309 DOI: 10.1111/j.1749-0774.2009.00071.x

18693 Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer Gastroenterology 2008 135(4):1358-1368 PubMed ID: 18692501 DOI: 10.1053/j.gastro.2008.06.082